Latest Capital Raise News

Cosmos Exploration deepens its foothold in Bolivia’s lithium sector through advanced brine testing and a strategic pilot plant purchase, positioning itself at the forefront of sustainable lithium extraction.

E79 Gold Mines Limited reported a net cash outflow of AUD 827,000 for the September 2025 quarter but bolstered its financial position through a successful capital raising in October. The company plans to reduce exploration expenditure in the coming quarter while maintaining operational continuity.

E79 Gold Mines has reported a productive September quarter highlighted by a binding agreement to acquire Cue Metals and promising drilling results at Laverton South and Mountain Home projects.

ikeGPS Group reports a robust first half of FY26 with a 47% increase in subscription revenue exit run rate and launches PolePilot™, an AI-driven automation tool enhancing utility network analysis.

ikeGPS has reported a robust first half of FY26 with subscription revenue soaring 47%, a successful A$24 million capital raise, and inclusion in the ASX All Ordinaries Index, underscoring its expanding footprint in the US grid modernization market.

ikeGPS Group reports a robust first half of FY26 with a 47% increase in subscription revenue exit run rate and launches AI-driven PolePilot™ to boost productivity and ARPU.

Golden Dragon Mining Ltd is set to raise $5 million through an IPO, aiming for ASX listing with a portfolio of promising gold and nickel exploration projects in Western Australia.

Brazilian Critical Minerals Limited reported a net cash outflow of AUD 1.2 million for Q3 2025, offset by strong financing inflows that boosted its cash reserves to AUD 2.46 million. The company’s extended loan facility and available credit provide a runway of over five quarters at current spending levels.

Matsa Resources has commenced mining at its Devon Pit Gold Mine, producing over 2,600 ounces of gold, while securing a $15 million funding package to accelerate development of its Lake Carey Gold Project.

Cambium Bio has locked in a significant R&D tax rebate and forged three strategic partnerships, underpinning its Phase 3 clinical trials for its lead ophthalmology biologic. The company’s recent capital raise further strengthens its runway as it prepares for pivotal trial milestones.

Zelira Therapeutics has made significant progress in its HOPE 1 clinical trial program, completing a key FDA submission and securing a $650,000 non-dilutive R&D loan facility to support ongoing development and working capital needs.

Orbminco Limited has completed a promising maiden drilling program at its Majestic North Gold Project, while refreshing its board and consolidating shares to sharpen its strategic focus on Australian gold assets.